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a b s t r a c t
In a project coordinated by the International Agency for Research on Cancer (IARC) 31 experts from 11
European countries and IARC have developed supplements to the current European guidelines for
quality assurance in cervical cancer screening. The supplements take into account the potential of
primary testing for human papillomavirus (HPV) and vaccination against HPV infection to improve
cervical cancer prevention and control and will be published by the European Commission in book
format. They include 62 recommendations or conclusions for which the strength of the evidence and the
respective recommendations is graded. While acknowledging the available evidence for more efﬁcacious
screening using HPV primary testing compared to screening based on cytology, the authors and editors
of the supplements emphasize that appropriate policy and programme organization remain essential to
achieve an acceptable balance between beneﬁt and harm of any screening or vaccination programme. A
summary of the supplements and all of the graded recommendations are presented here in journal
format to make key aspects of the updated and expanded guidelines known to a wider professional and
scientiﬁc community.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Background
In the current 28 Member States of the European Union (EU),
approximately 34,000 new cases of cervical cancer and 13,000 deaths
due to the disease occur annually [17]. Despite signiﬁcant progress in
Europe in recent decades in reducing the burden of cervical cancer,
rates of death attributed to the disease are still high in many of the
‘new’ Member States that joined the EU after 2003: estimates of the
annual age-standardized rates per 100,000 women in Hungary (6.9),
the Slovak Republic (6.9), Poland (7.4), Latvia (8.2), Bulgaria (8.8) and
Lithuania (9.8) are ﬁve to seven times higher, and in Romania (14.2)
ten times higher than in Finland (1.4) and Malta (1.2), the EU Member
States with the lowest rates in 2012. The age-standardized incidence
rates of cervical cancer reveal a similar picture. The current 10-fold
gradient in the mortality rates of cervical cancer among the EU
Member States largely reﬂects the persistent absence, or inadequate
implementation of cervical cancer screening programmes more than
10 years after organized, population-based screening programmes
following European quality assurance guidelines were unanimously
recommended by the Health Ministers of the EU [10].
Quality assurance aims to ensure that an endeavour leads to the
outcome for which it is intended; this is particularly important for
complex systems, such as screening programmes designed to
lower the burden of cancer in the population [44]. The second
edition of the European guidelines for quality assurance in cervical
cancer screening [4,5] was published seven years ago. The con-
tinuing clear need to improve implementation of cervical cancer
screening in the EU underlines the importance of re-emphasizing
the European guidelines through the publication of the present
supplements to the second edition. The supplements have been
developed in a time of transition. Vaccination of girls and possibly
also of boys in the future against the human papillomavirus (HPV)
types that cause approximately 70% of cervical cancer has become
an additional, complementary option of cervical cancer preven-
tion, the main impact of which will emerge in a few decades when
currently vaccinated girls are in their thirties and forties. In
addition, cytology1 is no longer the only test suitable for use in
cervical cancer screening in the EU. The evidence presented in the
ﬁrst of the present supplements shows that primary testing for
oncogenic HPV2 fulﬁls the requirements for evidence-based
screening tests laid down in the Council Recommendation [10],
provided that cervical cancer screening programmes follow the
recommendations for quality assurance published in the second
edition [4,5] and the present supplements of the European guide-
lines [2,11,34].
Of particular importance is the recent evidence from the
second round of European randomized controlled trials showing
a more pronounced effect of cervical screening using HPV primary
testing compared to cytology-based screening [35,6]. Given the
evidence for improved efﬁcacy of HPV primary screening that is
explained in the ﬁrst supplement, decision-makers, advocates,
professionals, and women in the EU are increasingly confronted
with the question of whether or not, and if so, how these new
developments should be integrated into more successful
approaches to control cervical cancer in Europe, both for the
individual women affected and for the population as a whole. By
focusing on the core topics of primary HPV testing in the ﬁrst
supplement [34], organization of HPV-based and cytology-based
screening programmes in the second supplement [2], and imple-
mentation of HPV vaccination programmes in the third supple-
ment [11], the joint publication of these supplements aims to
provide appropriate answers to these important questions and to
lay the foundation for further development of the comprehensive
European guidelines in the coming years.
Publication format
The supplements are presented in a joint volume including 62
main recommendations and conclusions for which the strength of
the evidence and the respective recommendations is graded
according to a deﬁned format. These recommendations are pre-
sented at the beginning of each supplement and their annotation
indicates the places in the subsequent text where the evidence
and the rationale pertaining to each recommendation are
explained, including cross-references to other supplements and
recommendations. This enables the reader to rapidly review the
key content of the supplements and to identify places in the
volume likely to be of interest for further reading. In addition,
some statements of advisory character are considered to be good
practice but not sufﬁciently important to warrant formal grading
are provided in each supplement.
1 Conventional cervical cytology with Papanicolaou staining (Pap smear) and
validated liquid-based cervical cytology (LBC) are evidence-based screening tests
that fulﬁl the requirements of the Council Recommendation on Cancer Screening of
2 December 2003 if performed in accordance with the European guidelines for
quality assurance in cervical cancer screening. The applicable items in the Council
Recommendation of 2 December 2003 are 1(a) for conventional cervical cytology
with Papanicolaou staining (Pap smear) and 1(a) in combination with 6(e) for
validated liquid-based cervical cytology (LBC) (see Annex 2 of the Supplements
volume [10]). Primary testing for oncogenic HPV with validated assays also fulﬁls
the requirements of the Council Recommendation of 2 December 2003 for
evidence-based screening tests, provided the recommendations in Supplements
1 and 2 to the second edition of the European guidelines for quality assurance in
cervical cancer screening are followed. The applicable items in the Council
Recommendation are 6(c) and 6(e) (see Annex 2 of the Supplements volume [10]).
2 Oncogenic HPV refers to the 13 high-risk HPV types (hrHPV): 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, and 68. These include the 12 HPV types currently classiﬁed
as carcinogenic to humans and one type (68) classiﬁed as probably carcinogenic to
humans in the IARC monograph series [7,19]. Unless otherwise indicated, the terms
HPV primary testing and HPV primary screening used in this supplement refer to
HPV testing conducted with systems based on validated hrHPV DNA assays.
Oncogenic HPV also induces other cancers than those of the cervix uteri, such as
vulvar, vaginal, anal and oropharyngeal cancers.
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Table 1
Screening for cervical cancer with primary testing for human papillomavirusA. Recommendations and conclusions. Supplement 1B.
Suitability of HPV primary testing for use in cervical cancer screening programmes
1.1 Primary testing for oncogenic HPVC can be used in an organized, population-based programme for cervical cancer screening (I-A) provided the other
recommendations in this supplement are followed (VI-A). Primary testing for oncogenic HPV outside an organized population-based programme is not
recommended (see also Suppl. 2, Rec. 2.1) (VI-E).Sect. 1.2.1.3; 1.2.3
Avoidance of co-testing (HPV and cytology primary testing) at any given age
1.2 Only one primary test (either cytology or testing for oncogenic HPV) should be used at any given age in cervical cancer screening (see also Rec. 1.3–1.7) (II-A).Sect. 1.3.1
Age at which to start HPV primary testing in cervical cancer screening programmes
1.3 Routine HPV primary screening can begin at age 35 years or above (see also Rec. 1.1) (I-A).Sect. 1.3.2.1
1.4 Routine HPV primary screening should not begin under age 30 years (I-E).Sect. 1.3.2.1
1.5 The available evidence is insufﬁcient to recommend for or against beginning routine HPV primary screening in the age range 30–34 years (VI).Sect. 1.3.2.1
Age at which to stop HPV primary testing in cervical cancer screening programmes
1.6 In the absence of sufﬁcient evidence on the optimal age at which to stop screening, HPV primary screening could stop at the upper age limit recommended for
cytology primary screening (60 or 65 years), provided a woman has had a recent negative test (VI-B).Sect. 1.3.2.2
Cervical screening using cytology primary testing outside the age range of HPV primary testing
1.7 Cervical screening based on cytology primary testing conducted outside the age range of HPV primary testing should follow the guidance provided for cytology-
based screening in the second edition of the European guidelines for quality assurance in cervical cancer screening, and in Supplement. 2 (see also Rec. 1.9, 1.10, 1.22
and 1.34) (VI-A). Sect. 1.3.2.1
Screening interval after a negative HPV primary test
1.8 The screening interval for womenwith a negative HPV primary test result should be at least 5 years (I-A) and may be extended up to 10 years depending on the age
and screening history (III-C).Sect. 1.3.3
Management of women without an adequate HPV primary test result
1.9 Some women attending cervical cancer screening may prefer not to be tested for HPV. If a woman declines HPV primary testing, cytology can be performed (see also
Rec. 1.7) (VI-C).Sect. 1.3.4
1.10 Non-attenders and women with a technically inadequate HPV test result should be invited to have a new sample taken (VI-A); alternatively cytology testing
without additional sample taking may be performed if technically feasible and preferred by the woman (see also Suppl. 2, Rec. 2.9–2.11) (VI-B).Sect. 1.3.4; 2.4
Management of women after a positive HPV primary test
1.11 Cervical screening programmes using HPV primary testing must adopt speciﬁc policies on triage, referral and repeat testing of women with positive primary test
results, taking into account the guidance in Rec. 1.12–1.31. The policies must include guidance on when women with positive HPV test results should be invited to
return to routine screening. (VI-A). Sect. 1.3.5
1.12 Screening programmes should carefully monitor management of HPV-positive women. Monitoring should include compliance of individual women with further
follow-up of positive primary test results, as well as results of triage, referral, colposcopies, biopsies, and treatment of precancers (VI-A).Sect. 1.3.5
1.13 Triage, referral and repeat testing policies (see Rec. 1.11) should be regularly reviewed and, if necessary, revised taking into account the results of monitoring (see
Rec. 1.12) and the available evidence (VI-A).Sect. 1.3.5
Secondary testing
 Cytology triage
1.14 Women testing positive for oncogenic HPV at primary screening should be tested without delay for cervical cytology (cytology triage) (I-A).Sect. 1.4.1.1 The cytology
test should preferably use the specimen collected during the HPV screening visit (VI-A).Sect. 1.4.1.1
1.15 Direct referral to colposcopy of all HPV-positive women is not recommended (I-D).Sect. 1.4.1.1
1.16 Depending on the result of cytology triage, HPV-positive women should be referred to repeat testing, or to colposcopy (see Rec. 1.18–1.21) (I-A).Sect. 1.4.1.1
1.17 Quality assurance of laboratories and professional practice in the provision of cytology, colposcopy and histopathology services used in cytology triage in HPV
primary screening should comply with the recommendations in Chap. 3–6 of the European Guidelines second edition (see also Rec. 1.35) (VI-B).Sect. 1.4.1.1
 Referral of women with pre-invasive or more severe cytology at triage
1.18 Women with ASC-H (atypical squamous cells, high-grade squamous lesion cannot be excluded), HSIL (high grade squamous intraepithelial lesion), AIS
(adenocarcinoma in situ) or a more severe ﬁnding at cytology triage should be referred to colposcopy without further observation or testing (III-A).Sect. 1.4.1.2
 Referral of women with minor cytological abnormalities at initial triage
1.19 Women with ASC-US (atypical squamous cells of undetermined signiﬁcance), AGC (atypical glandular cells), or LSIL (low grade squamous intraepithelial lesion) at
triage after an initial HPV primary test in a screening episode may be followed up by retesting, preferably after 6–12 months, or referred directly to colposcopy (see
Rec. 1.22–1.31) (VI-C).Sect. 1.4.1.2
Referral of women with negative cytology at initial triage
1.20 Women who have negative cytology (negative for epithelial abnormality) at triage after a positive initial HPV primary test in a screening episode should be
followed up by re-testing after an interval shorter than the regular screening interval, but after at least 6–12 months (see also Sect. 1.4.1 and Rec. 1.23 and 1.24)
(VI-A).Sect. 1.4.1.2
1.21 Direct referral to colposcopy of women with negative cytology at triage is not recommended (I-D) Sect. 1.4.1.2
Management of women at repeat testing
1.22 The prevalence of HPV and the quality and organization of cytology screening affect the efﬁciency, effectiveness and appropriateness of management of women at
repeat testing. These factors should be taken into account in the regular review of management protocols for repeat testing (see also rec. 1.13) (VI). Sect. 1.4.3
 Type and interval of repeat testing
1.23 Cytology repeat testing after at least 6–12 months is an acceptable alternative to HPV repeat testing (see also Chap. 6, Sect. 6.3.1 in European Guidelines, second
edition) (III-B). Sect. 1.5.1
1.24 Womenwho were HPV-positive and cytology normal (negative for epithelial abnormality) in primary screening may be managed by HPV retesting with or without
cytological triage, and after an interval of preferably at least 12 months (III-B).Sect. 1.5.1
 Protocols using HPV testing with cytology triage in repeat testing
1.25 Women should be referred to colposcopy if cytology triage of a positive repeat HPV test yields ASC-US (VI-B) or more severe cytology (VI-A).Sect. 1.5.3
1.26 Women who have negative cytology triage (negative for epithelial abnormality) of a positive (repeat HPV test) may be managed by one of the following options
(see also Rec. 1.11–1.13) (VI-B).Sect. 1.5.3
 Referral to second repeat testing after at least 12 months
 Referral to colposcopy
 Return to routine screening
1.27 Women who have a negative repeat HPV test should return to routine screening (III-A). Cytology triage is not needed for these women (III-E).Sect. 1.5.3
 Protocols using cytology testing alone in repeat testing
1.28 Women with ASC-US or more severe cytology at repeat testing should be referred to colposcopy (VI-B).Sect. 1.5.3
1.29 Women with normal cytology at repeat testing should return to routine screening (III-A).Sect. 1.5.3
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Methodology
To develop the evidence-based recommendations, the approach
used for the European guidelines for quality assurance in colorectal
cancer screening and diagnosis [27] was adopted and modiﬁed
slightly to take into account the different subject matter and time
period of the present project. A multidisciplinary group of authors
and editors experienced in quality assurance in cervical cancer
screening, programme implementation and guideline development
collaborated with a ‘literature group’ consisting of epidemiologists
with special expertise in the ﬁeld of cervical cancer screening and in
systematic literature review. Experts in HPV vaccination were also
recruited to participate in the project together with the other editors,
authors and reviewers. The literature group systematically retrieved,
evaluated and synthesized relevant publications dealing with cervical
cancer screening according to clinical questions deﬁned by the
authors and editors. The clinical questions were subsequently elabo-
rated according to the Patient-Intervention-Comparison-Outcome-
Study (PICOS) method [18,30,31] that was modiﬁed slightly to take
into account the aim of screening to lower the burden of the disease
in the population.
Bibliographic searches for most clinical questions were limited
to the time period January 2000 to March 2012 and were
performed on Medline, and in many cases also on Embase and
the Cochrane Library. Priority was given to recent comprehensive
reviews. Additional searches were conducted without date restric-
tions or starting before 2000 if the authors or editors who were
experts in the ﬁeld knew that there were relevant papers pub-
lished before 2000. Where no observational data were available,
outcomes simulated by mathematical models and expert opinion
were accepted as the lowest level of evidence. Papers of adequate
quality recommended by authors because of their clinical rele-
vance were also included, especially in the time period after March
2012 and up to December 2014 prior to completion of ﬁnal editing
of the draft manuscripts that began in July 2014. Preliminary
versions of the draft supplements were repeatedly reviewed and
revised through multidisciplinary meetings and discussions in
which authors, editors and members of the literature group
participated. Prior to ﬁnalization and review by the complete
group of editors, the draft manuscripts were intensively reviewed
by selected editors and/or external experts.
The editorial board was responsible for the ﬁnal formulation of
the supplements and the grading of the evidence and strength of
the recommendations. The level of evidence and the strength of
each of the graded recommendations are indicated using the
slightly modiﬁed scales adopted for the European guidelines
for quality assurance in colorectal cancer screening [27,41];
see below:
Grading of recommendations and supporting evidence
For the level of evidence:
I. Consistent multiple randomised controlled trials (RCTs) of
adequate sample size, or systematic reviews (SRs) of RCTs,
taking into account heterogeneity
II. One RCT of adequate sample size, or one or more RCTs with
small sample size
III. Prospective cohort studies or SRs of cohort studies; for
diagnostic accuracy questions, cross-sectional studies with
veriﬁcation by a reference standard
IV. Retrospective case-control studies or SRs of case-control stu-
dies, trend analyses
V. Case series; before/after studies without control group, cross-
sectional surveys
VI. Expert opinion
For the strength of the respective recommendation:
A. Intervention strongly recommended for all patients or targeted
individuals
Table 1 (continued )
Suitability of HPV primary testing for use in cervical cancer screening programmes
 Protocols using HPV testing alone in repeat testing
1.30 Women who have a negative repeat HPV test should return to routine screening (II-A). Sect. 1.5.3
1.31 Women who have a positive repeat HPV test should be referred to colposcopy (II-C).Sect. 1.5.3
Self-sampling in screening programmes using HPV primary testing
1.32 The clinical accuracy of HPV primary testing on self-collected samples taken for cervical screening is sufﬁcient to conduct organized, population-based pilot programmes
for women who have not attended screening despite a personal invitation and a personal reminder (see also Rec. 1.33 and Suppl. 2, Rec. 2.8–2.13) (III).Sect. 1.7
Selection of HPV tests suitable for primary cervical cancer screening
1.33 Cervical cancer screening programmes should adopt an HPV primary test for use only if it has been validated by demonstrating reproducible, consistently high
sensitivity for CIN2þ and CIN3þ lesions, and only minimal detection of clinically irrelevant, transient HPV infections (VI-A).Sect. 1.2.1.3; 1.6
Implementation of HPV primary testing in cervical cancer screening programmes
1.34 HPV primary screening programmes should follow the guidance in the European Guidelines, that is relevant to any cervical screening programme irrespective of
the method of primary testing used. The relevant guidance includes the recommendations on programme organization, planning, monitoring and evaluation (see
current Suppl. 2, and second edition, Chap. 2); communication; and quality assurance of the entire screening process including sampling, histopathologic
interpretation and classiﬁcation of cervical tissue; and management of detected lesions (see second edition, Appendix 1 and Chap. 3–6) (VI-A).Sect. 1.2.3
1.35 Like cervical cytology testing, HPV testing should be performed only on samples processed and analysed in qualiﬁed laboratories, accredited by authorized accreditation
bodies and in compliance with international standards. The laboratory should perform a minimum of 10,000 tests per year (see also Rec. 1.34) (VI-A).Sect. 1.6
1.36 Any decision to implement HPV primary testing in cervical cancer screening should take into account health economic factors, and whether correct use of the test
as speciﬁed in the instructions of the manufacturer and in accordance with the recommendations in this supplement can be organized (VI-B).Sect. 1.2.1.3; 1.3.2.1
 Health economic factors to consider in planning and subsequent steps in programme implementation include the prevalence of HPV infections; the burden of
repeat testing, colposcopies, and CIN treatments resulting from HPV testing; and the quality and impact of existing cytology screening programmes.
 Assessments should be conducted to determine the optimal target age groups and screening intervals based on the chosen test and management protocols.
 The feasibility and sustainability of the programme should be assured through adequate resourcing and coordination, including coordinated planning, feasibility
and pilot studies, and quality-controlled rollout across a country or region (see Suppl. 2 and Annex 1).
A Source: [34].
B Sect. (superscript) after each recommendation in the list refers the reader to the section/s of the Supplements dealing with the respective recommendation. Rec.
followed by a number refers to the number of the respective recommendation.
C Oncogenic HPV refers to the 13 high-risk HPV types (hrHPV): 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. These include the 12 HPV types currently classiﬁed as
carcinogenic to humans and one type (68) classiﬁed as probably carcinogenic to humans in the IARC monograph series [7,19]. Unless otherwise indicated, the terms HPV
primary testing and HPV primary screening used in this supplement refer to HPV testing conducted with systems based on validated hrHPV DNA assays. Oncogenic HPV also
induces other cancers than those of the cervix uteri, such as vulvar, vaginal, anal and oropharyngeal cancers.
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B. Intervention recommended
C. Intervention to be considered but with uncertainty about
its impact
D. Intervention not recommended
E. Intervention strongly not recommended
Screening for cervical cancer with primary testing for human
papillomavirus
The ﬁrst of the present supplements [34] aims to inform
European policy makers and public health specialists, and any
other interested parties about the critical issues that should be
considered in weighing the potential beneﬁt and harm of cervical
screening programmes based on HPV primary testing. It includes
36 graded recommendations dealing with the suitability of HPV
primary testing for use in cervical cancer screening. Key messages
and topics covered in the supplement include the lack of appro-
priate beneﬁt from co-testing, and the appropriate target age
group and interval for HPV primary testing. Management proto-
cols for women with positive or technically inadequate HPV
primary tests, the clinical accuracy of HPV testing using self-
collected samples, and the selection of tests suitable for primary
screening are also covered; and other policies and professional and
scientiﬁc standards, such as consideration of health economic
issues, are indicated that should be adhered to in the design and
implementation of quality-assured cervical cancer screening pro-
grammes based on HPV primary testing. It is not the intention of
the authors and editors to promote recent research ﬁndings before
they have been demonstrated to be of proven beneﬁt in clinical
practice. The supplement therefore focuses on the use of primary
testing for HPV DNA in cervical cancer screening with cytology
triage in the EU. As far as possible the authors and editors have
attempted to achieve an equitable balance that is applicable across
a wide spectrum of cultural and economic healthcare settings in
the EU. As with any standards and recommendations, these should
be continuously reviewed in the light of future experience.
The scientiﬁc justiﬁcation for the recommendations in the ﬁrst
supplement is provided by over 110 publications cited in the text,
including published cross-sectional and longitudinal data from
eight randomized clinical trials conducted in Canada, Finland,
India, Italy, Sweden, The Netherlands and the United Kingdom
[1,8,12,20–24,26,28,29,32,33,35–40]. It should be noted that the
efﬁcacy of HPV primary testing in cervical cancer screening has
been demonstrated in studies using clinician-based samples. The
authors and editors emphasize that currently the clinical accuracy
Table 2
Organization of cytology-based and HPV-based cervical cancer screeningA. Recommendations and conclusions. Supplement 2B.
2.1 Irrespective of the method of primary testing (cytology or HPV assay) cervical cancer screening should always be performed in an organized, population-based screening
programme with comprehensive quality assurance covering all steps in the screening process (see also Suppl. 1, Rec. 1.34, and Annex 1 and 2) (VI-A).Sect. 2.3
2.2 If organized, population-based cervical screening programmes do not currently exist in a country or region, decision-makers should review the relevant policy on
cervical cancer screening taking into account the Council Recommendation on Cancer Screening (Annex 2), the European Guidelines for quality assurance in cervical
cancer screening, second edition, and the present Supplements (see also Annex 1) (VI-A).Sect. 2.3
2.3 In countries or regions in which population-based cervical screening programmes using cytology primary testing are currently established, decision-makers should
consider whether implementation of HPV primary testing in existing programmes would improve the balance between harm and beneﬁt, and if so, integrate the
change into the comprehensive cancer control programme (see also Suppl. 1, Rec. 1.1 and 1.36) (VI-A).Sect. 2.3
Quality-assured process of screening programme implementation
2.4 If a decision is made to implement HPV primary testing in an existing population-based cervical screening programme, comprehensive planning, feasibility testing
and pilot programmes should be conducted prior to routine implementation to ensure that an appropriate balance between harm and beneﬁt is achieved in the
transition to HPV primary screening, including effective and efﬁcient use of resources (see also Annex 1) (VI-A).Sect. 2.3.1
2.5 If a decision is made to implement a population-based cervical screening programme in a country or region previously lacking such a programme, special attention
must be paid not only to selecting the method of primary testing (cytology or HPV testing), but also to testing and developing the capacity for a population-based
approach to programme implementation including building up comprehensive quality assurance (see also Rec. 2.4 and Annex 1 and 2) (VI-A).Sect. 2.3.2
2.6 The introduction of new population-based screening programmes should be coordinated by a unit with a comprehensive mandate and sufﬁcient autonomy and
resources to ensure that the European quality assurance guidelines are followed and that international experts familiar with the process and determinants of
successful programme implementation can be consulted (see also Annex 1) (VI-A).Sect. 2.3.3
Population based approach to cervical cancer screening
 Avoiding ﬁnancial barriers to participating in screening
2.7 Screening should be free of charge or subject to only a limited charge for women who attend, regardless of whether cytological or HPV screening is offered (I-A).Sect. 2.4.1
 Personal invitation letters
2.8 Personal invitation letters to participate in screening should include a scheduled appointment (date, time and place) and instructions about how to change the
appointment if necessary (I-A).Sect. 2.4.2
 Personal reminders
2.9 Women who do not attend screening should receive a personal reminder (I-A). The reminder should be sent by letter and should include a scheduled appointment
(date, time and place) and instructions about how to change the appointment if necessary (II-A).Sect. 2.4.3
2.10 A second personal invitation reminder should be sent if there is no response to an initial reminder (I-B).Sect. 2.4.3
2.11 Personal invitation reminders may also be delivered by telephone call, provided womenwho are not reached by telephone are sent a reminder letter (I-B).Sect. 2.4.3
 Self-sampling
2.12 Piloting self-sampling for women who did not participate in primary HPV screening despite a personal invitation and a personal reminder is recommended,
provided it is conducted in an organized, population-based screening programme with careful monitoring and evaluation of the aimed performance and outcomes
(see Rec. 2.8–2.11 and Suppl. 1, Rec. 1.32 and 1.36) (I-A).Sect. 2.4.4
2.13 Prior to rollout towards national implementation, a self-sampling pilot project should demonstrate successful results compared to clinician-based sampling
(positivity rate, positive predictive value of a positive test result, and cost-effectiveness). The pilot should also demonstrate that key organizational problems, such
as the appropriate screening interval and compliance with invitation and management protocols for women with positive test results, have been adequately
resolved (III-D).Sect. 2.4.4
Monitoring cervical cancer screening performance
2.14 Monitoring of population-based cervical screening programmes should include the performance parameters deﬁned in the European guidelines for quality
assurance in cervical cancer screening (Suppl. 2, and Chap. 2 and 7 of the second edition 2) (VI-A).Sect. 2.6
2.15 Programmes should achieve an invitation coverage of 95% (acceptable level) (III-A); 495% is desirable (III-A).Sect. 2.6.1
2.16 Programmes should achieve an examination coverage of 70% (acceptable level) (III-A); 485% is desirable (VI-A).Sect. 2.6.1
2.17 Programmes should achieve a participation rate of 70% (acceptable level) (III-A), 485% is desirable (VI-A).Sect. 2.6.1
A Source: [2].
B See footnote B of Table 1.
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of HPV primary testing on self-collected samples is sufﬁcient to
conduct organized, population-based pilot programmes for
women who have not attended screening despite a personal
invitation and a personal reminder (Rec. 1.32 in Suppl. 1 [34], see
also Table 1). Policy makers and professionals must be aware,
however, that HPV testing on self-taken samples is less accurate
than on clinician-taken samples. For this reason, self-sampling is
not recommended for all women invited to screening (see Sect.
1.7 in [34] and Sect. 2.4.4 and Rec. 2.8–2.13 in Suppl. 2 [2], see also
Table 2).
The authors and editors also emphasize that despite the convincing
evidence for more efﬁcacious screening using HPV primary testing,
appropriate screening policy and programme organization are essential
to achieving an acceptable balance between beneﬁt and harm of any
screening programme. These principles are particularly important in
HPV primary screening, in order to avoid substantial increase in the
number of women with positive test results and additional colposco-
pies and treatment of no additional beneﬁt to participating women.
Following the recommendations in the present supplement will enable
programmes to achieve the potential beneﬁt of HPV primary testing in
cervical cancer screening while minimizing the risks (see Rec. 1.11 in
[34], see also Table 1).
While most of the recommendations in the ﬁrst supplement focus
on the opportunities and the challenges of HPV primary screening that
set it apart from cytology-based screening; decision-makers, pro-
gramme managers and professionals should also be aware of the
guidance in the previously published volume of the second Guidelines
edition [4,5] that is relevant to any cervical screening programme
irrespective of the method of primary testing used (see Rec. 1.34). Of
prime importance in this regard are also the recommendations on
programme organization, planning, monitoring and evaluation in the
second supplement. The authors and editors also emphasize the
importance of using reliable, validated HPV tests (see Rec. 1.33) in
qualiﬁed laboratories, accredited by authorized accreditation bodies
and in compliance with international standards (see Rec. 1.35) In
addition, any decision to implement HPV primary testing in cervical
cancer screening should take into account health economic factors,
and whether correct use of the test as speciﬁed in the instructions of
the manufacturer and in accordance with the recommendations in the
supplement can be organized (see Rec. 1.36). The authors and editors
also point out that sustainability is crucial to the success of any cervical
screening programme, and in the ﬁrst supplement they underline the
importance of the respective recommendations in Supplement 2 and
in Annex 1 of the Supplements volume.
Organization of cytology-based or HPV-based cervical cancer
screening
The second supplement [2] addresses the persisting gap in the EU
between knowledge of the potential of population-based cervical
screening to reduce the burden of the disease in the population, on
the one hand, and the extent to which this knowledge has been
translated into effective national programmes to control cervical cancer,
on the other hand. As pointed out in the Council Recommendation on
cancer screening (Annex 2 of the Supplements volume, see also [10]),
the most effective and appropriate way for screening to reduce cervical
cancer incidence and mortality is through implementation of popula-
tion-based programmes according to the European quality assurance
guidelines. Despite this knowledge, many old and new Member States
of the European Union do not have population-based screening
programmes in place or have programmes that are underperforming.
The supplement provides 17 recommendations on the policy and
organizational issues that are inherent to the use of cytology and
HPV testing in screening programmes. First and foremost is recognition
of the need to implement HPV primary screening only in organized,
population-based programmes (see Rec. 2.1 in Suppl. 2 [2], see also
Table 2). This is an important prerequisite for effective quality assurance
of any cancer screening programme (see Annex 1 [25,43] and of the
Supplements volume) and one that applies particularly to HPV primary
screening.
The scientiﬁc justiﬁcation for the recommendations in the
second supplement is provided by over 90 publications cited in
the text. In light of the evidence that HPV primary screening of
appropriate quality can yield better results than cytology-based
screening, policy-makers in EU countries or regions with cytology-
based population programmes are advised to review current
policies and consider whether transition to HPV primary screening
would improve the balance between harm and beneﬁt in their
programmes. Policy makers in EU countries or regions lacking any
population-based cervical screening programme are advised to
review current policies and consider implementation of organized
population-based cervical screening programmes taking into
account the current European guidelines [4,5], including the
supplements [2,11,34], and the Council Recommendation [10]
(see Rec. 2.2 and 2.3). In addition to these general aspects,
problems are discussed that are commonly encountered in imple-
menting cervical cancer screening programmes in EU Member
States with population-based programme policies, in those with
opportunistic programmes, or in Member States in Central and
Eastern Europe, and solutions are suggested that have proven to be
effective in successful European screening programmes. The
recommendations in the supplement are focussed on strategies
to optimize screening attendance, including invitations, reminders
and self-sampling. For evaluation and monitoring, the supplement
also provides key performance indicators speciﬁcally related to
HPV primary screening; and for the ﬁrst time, European quality
standards are introduced for key performance indicators (coverage
by invitation, coverage by examination; and rate of participation or
uptake) (see Rec. 2.15–2.17).
In the text more detailed advice is provided on the steps that
programme management should take in navigating the protracted
process of establishing an organized, population-based screening
programme, including a checklist for planning, feasibility testing,
piloting, monitoring and evaluation (see Sect. 2.7). This guidance
illustrates and supplements the recommendations in Annex 1 dealing
with the determinants of successful implementation of cancer screen-
ing programmes [25,43]; see also [3,45].
Implementation of vaccination against human papillomavirus
in Europe
The third of the present supplements [11] summarizes the
evidence base for HPV vaccination using the currently licensed
bivalent and quadrivalent vaccines in the EU.3 Over 90 publications
are cited and nine graded recommendations are provided to promote
effective implementation of this tool for cervical cancer control in the
EU. Clinical trials have shown the current prophylactic HPV vaccines to
be safe and highly effective against persistent vaccine-related HPV
infections and anogenital precancerous lesions among women who
were not infected by these types at the time of vaccination [13,46,48];
see also [15,16]. The use of HPV vaccines in pre-adolescent girls and
young women for the primary prevention of cervical cancer and some
other HPV-related diseases has been endorsed by the European
3 The 9-valent vaccine that was recommended by the European Medicines
Agency (EMA) in March 2015 for the prevention of diseases caused by nine types of
human papillomavirus (HPV) was not considered in the preparation of the present
supplement because at the time of writing and editing the Supplements it was not
licensed for use in the EU. See accessed 28/05/2015: http://www.ema.europa.eu/
docs/en_GB/document_library/Press_release/2015/03/WC500184898.pdf.
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Medicines Agency (EMA) in 2006 (quadrivalent HPV 6/11/16/18
vaccine)4 and 2007 (bivalent HPV 16/18 vaccine),5 and in a position
paper by the World Health Organization (WHO) in 2009 and 2014
[47,49]. Since then, 21 of the 28 Member States of the European Union
plus Norway and Iceland have introduced national HPV vaccination
programmes. Recently, WHO updated its HPV vaccines position paper
to recommend a two-dose regimen with increased ﬂexibility in the
interval between doses [49]. EMA has also granted marketing author-
izations for bivalent and quadrivalent vaccines in the EU for a two-
dose schedule administered by injection at a 6-month interval for girls
aged 9–14 and 9–13 years, respectively. If the respective vaccines are
administered at an older age, the three-dose schedule should be used
[15,16]. Some EU countries, such as Belgium, France, Italy and the UK,
have already implemented a 2-dose HPV vaccination schedule.
The primary target group for routine vaccination is girls at an age
before debut of sexual activity, usually 12–13 years. Targeting older
girls and young women with catch-up vaccination at the start of a
routine vaccination programme can accelerate the impact of the
vaccination programme, as clinical trials have shown satisfactory
immune response and efﬁcacy against infection in women aged
15–26 years being HPV 16 and 18 DNA negative. The question
whether boys should also be included in the HPV vaccination target
population is currently under debate and is the subject of ongoing
research. Vaccination of boys could contribute to herd immunity and
offer protection against other HPV-related cancers and genital warts in
the vaccinated subjects. Moreover, mathematical modelling studies
indicate that vaccinating boys would be cost-effective if vaccine
coverage in girls is lower than 30–50%, as is the case in a number
of EU Member States, or if vaccine cost is substantially diminished, i.e.,
is halved.
Clinical trials and post-licensure studies have shown that the
current vaccines are safe, and efforts are still on-going to monitor rare
events like auto-immune diseases, or possible adverse effects in
special groups such as women who have been inadvertently vacci-
nated while being pregnant. An important measure in process-
monitoring of HPV vaccination is the assessment of vaccine coverage
data by year of birth and number of administered doses. In addition,
individual vaccination records should be retained, to permit linkage of
HPV-related disease incidencewith individual vaccination status in the
future.
A measurable early indicator of the impact of vaccination will be
the prevalence of HPV infections in young vaccinated women. Indirect
evidence of population level impact of the HPV vaccines has already
been provided through the demonstration of a decrease in the
prevalence of HPV, the incidence of high-grade cervical abnormalities,
and the incidence of genital warts soon after the introduction of
vaccination programmes. However, long-term monitoring of end-
Table 3
Organization of HPV vaccinationA. Recommendations and conclusions. Supplement 3B.
3.1 HPV vaccination is best implemented through organized, population-based programmes (III-A).Sect. 3.6
 A population-based programme is likely to achieve higher coverage, less social inequalities in vaccine uptake, and lower vaccination costs per vaccine (III).Sect. 3.6
 If a country has started implementation with the opportunistic approach, transition to an organized, preferably school-based (or other public-service-based) programme
is recommended (III-A).Sect. 3.6
Target age for HPV vaccination
3.2 The primary target group to consider for routine population-based vaccination is girls at an age before the onset of sexual activity, usually between 10 and 13 years
(I-A).Sect. 3.2.1
 Targeting older girls and young women with catch-up vaccination at the start of a routine vaccination programme can accelerate the impact of the vaccination
programme (I).Sect. 3.2.2
Monitoring and evaluation of HPV vaccination programmes
3.3 Organized, population-based HPV vaccination programmes should have systematic register-based monitoring of coverage and safety. Long-term evaluation of
vaccine safety and effectiveness is recommended in all countries. Appropriate legal frameworks must be developed, taking funding and organizational resources
into account (VI-A).Sect. 3.3
 Coordination between vaccine evaluation and cancer control programmes is recommended. It will be critical to assess the impact of the vaccine and its synergies
with screening and health education (VI-A).Sect. 3.3
 Long-term evaluation based on systematic registration of HPV vaccination and linkage studies using relevant healthcare registries should be used to assess vaccine
effectiveness and safety in various settings. If a country has the capacity, it is desirable that assessment of vaccine impact include: surveillance for vaccine-related
and other oncogenic HPV infections, precancerous lesions, and HPV-related cancers (VI-A).Sect. 3.3
 The minimum set of information for monitoring HPV vaccination should include data on vaccine coverage, monitoring of adverse events following immunization
and, if possible, a sentinel surveillance of impact on precancerous lesions (VI-A).Sect. 3.3
3.4 Standard deﬁnitions and parameters for coverage of vaccination should be developed and used in vaccination monitoring (VI-A).Sect. 3.5
 Age at primary vaccination, age at catch-up vaccination, number of doses by single year of age and time between doses, and duration of follow-up since offering
primary vaccination should be included in the deﬁnitions and performance parameters (VI-A).Sect. 3.5
Planning, piloting, and modifying HPV vaccination programmes
3.5 Planning and modiﬁcation of vaccination programmes and policies should take into account local conditions, including vaccine and vaccination costs and resources
required in monitoring, provision of information, and communication. Pilot studies are recommended to assess how to improve coverage and public awareness
(VI-A).Sect. 3.6
Procurement
3.6 Decision-makers should be aware of the wide range of prices for HPV vaccines in the EU and the potential to reduce the overall costs of HPV vaccination
programmes by negotiating vaccine prices that are comparable to the low prices obtained in some EU Member States (VI-A).Sect. 3.6
Coverage target for HPV vaccination programmes
3.7 HPV vaccination programmes should aim for a minimum coverage of 70% and preferably 480% (III-A).Sect. 3.5
 The reported 3-dose coverage of primary vaccination in a population-based vaccination programme should reach 70% within the ﬁrst 12 months (III-A). The same
coverage target applies for programmes using a 2-dose schedule (VI-A).Sect. 3.5
HPV screening and HPV vaccination
3.8 Vaccination status should be known to screening and vaccination registries for women reaching the target screening age (VI-A).Sect. 3.3
3.9 Planning and research on synergies between HPV vaccination and HPV screening is recommended to improve the effectiveness and cost-effectiveness of prevention
of HPV-related disease (VI-A).Sect. 3.2
A Source: [11].
B See footnote B of Table 1.
4 See summary of product characteristics, accessed 10/04/2015: http://www.
ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/
human/000703/WC500021142.pdf.
5 See summary of product characteristics, accessed 10/04/2015: http://www.
ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/
human/000721/WC500024632.pdf.
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point indicators is essential to assure that programmes attain their
expected impact. This will require careful assessment of changes in the
epidemiology of severe precancerous lesions and cancers over decades
through linkage between screening and cancer registries irrespective
of early indicator studies.
As of early 2014, seven EU countries had not yet initiated HPV
vaccination campaigns, all of them new Member States (Estonia,
Hungary, Lithuania, Poland, Slovakia, Cyprus and Croatia). HPV vacci-
nation is perceived as being too expensive by many new Member
States, but vaccine prices for vaccination campaigns have decreased
considerably in recent years, and modelling studies have shown that
cost-effectiveness of HPV vaccination tends to be largest in countries
with the highest cervical cancer burden, as is the case in most of these
countries.
In most of the EU Member States with HPV vaccination campaigns,
the vaccine is offered free of charge, predominantly through organized,
population-based programmes distributing the vaccine at schools or
public health centres. The success in terms of coverage of the target
groups has been highly variable, ranging from o30% to 80% and over.
At the lower end of the range, in France and Luxemburg, the
programmes rely on opportunistic vaccination. The highest rates of
80% and above are in countries or regions with population-based
vaccination programmes (Denmark, Malta, Portugal, Sweden and the
UK and Flemish community in Belgium). Most of the countries choose
routine target groups that include ages in the range 11–13 years.
Organized school-based programmes usually provide the best cover-
age and more equitable access to HPV vaccines, followed by organized
programmes through health-care centres and through general practi-
tioners. Opportunistic programmes usually achieve low or ill-deﬁned
levels of coverage. Vaccination campaigns targeting adolescents pose
speciﬁc challenges, compared to those targeting younger children
aged 10–13 years.
Given the current variation in HPV vaccination coverage in the EU,
the importance of an organized, population-based approach to vaccine
delivery and the need for adaptation of existing vaccine delivery
infrastructure to the special requirements of HPV vaccination are
common to all EU countries (see Rec. 3.1 in Suppl. 3 [11], see also
Table 3). Higher vaccination coverage is a reasonable goal in many EU
Member States. HPV vaccination programmes should aim at a mini-
mum coverage of 70% and preferably 480% (see Rec. 3.6). Effective
monitoring and evaluation will be key to improving the coverage and
effectiveness of vaccination programmes across the EU. Organized,
population-based HPV vaccination programmes should have systema-
tic register-based monitoring of coverage and safety. Long-term
evaluation of vaccine safety and effectiveness is recommended in all
countries. Appropriate legal frameworks must be developed, taking
funding and organizational resources into account (see Rec. 3.3). Every
effort should be made to record individual vaccination status to ensure
that it will be known for future cohorts reaching the target age for
screening (see Rec. 3.8).
Discussion and conclusions
In an evidence-based process, supplements have been developed
that expand the current second edition of the European guidelines
for quality insurance in cervical cancer screening [4,5] to cover topics
essential to successful implementation of population-based pro-
grammes for HPV primary screening and vaccination. In addition to
a large package of recommendations graded according to the
strength of the recommendations and the supporting evidence,
numerous recommendations considered to be good practice by the
authors and editors but not of sufﬁcient importance to warrant
formal grading are provided in the 200-page Supplements volume
that will be published by the European Commission. Neither the
Supplements volume nor the previously published volume of the
second Guidelines edition should be regarded as a text book or in any
way a substitute for practical clinical training and experience, but
together they provide important European reference documents that
decision makers in EU Member States and other countries should
consult to determine whether current policies and prgrammes for
cervical cancer prevention and control can be improved before a new
and fully revised third edition of the European guidelines becomes
available.
The need for further improvement in cervical cancer preven-
tion and control in Europe, particularly in many of the newer EU
Member States is the rationale for focusing the present supple-
ments on topics relevant to HPV primary screening and vaccina-
tion. The completion of the supplements by a multidisciplinary
group of experts in cervical screening, HPV vaccination and quality
assurance and their publication by the European Commission has
the potential to become a watershed in improvement of cervical
cancer prevention and control in Europe. Based on robust evidence
the editors of the supplements explain that cytology primary
testing is no longer the only method for population-based cervical
cancer screening that fulﬁls the requirements of the Council
Recommendation on Cancer Screening of 2 December 2003. HPV
primary testing is also an appropriate, evidence-based screening
method, provided the recommendations in the supplements are
followed in programme implementation.
Recognition of the conformity of cervical cancer screening based
on HPV primary testing with the Council Recommendation on Cancer
Screening is of prime importance because the ﬁrst report on cancer
screening in the EU documented considerable interest in the EU
members states in following through on the Council Recommenda-
tion by establishing and improving cancer screening programmes in
accordance with European Guidelines for quality assurance [9,42].
Raising awareness for the supplements through publication of the
present summary should encourage responsible authorities and
programme managers to review current policies to determine
whether further improvement in cervical cancer prevention and
control may be achieved through modiﬁcation of existing screening
programmes or implementation of new, HPV-based programmes
where cervical screening programmes are lacking; and through
optimized implementation of HPV vaccination.
The choice of content of the present summary is to some extent
arbitrary and cannot in any way be regarded as an alternative to
the requirement for reading each supplement as a whole and
within the context of the complete second edition of the European
quality assurance guidelines [4]. This will be possible when the full
Supplements volume is available. It should be kept in mind
however, that despite encouraging progress, the availability of
the extensive supplements will not provide answers to all of the
questions that are relevant to future improvement in cervical
cancer prevention and control in Europe. Additional points, such
as the potential role of methods other than cytology in triaging
women with positive HPV test results and evaluation of new
primary tests and vaccines require further attention.
It has recently been pointed out that the variation in Europe in the
implementation of cancer screening offers a unique opportunity to
learn from best practices in collaboration between cancer registries
and screening programmes [3] and in quality assurance [14]. In order
to accelerate improvements in cancer control, cancer registries should
take co-responsibility with screening and vaccination programmes
and registries in promoting continuous improvement of primary and
secondary cancer prevention in Europe. Additional sustainable invest-
ments are vital to further development of infrastructures and activities
for quality assurance, including organization training, evaluation and
monitoring in the national settings and also at the pan-European level.
This is an important point that is also emphasized in Annex 1 [43] of
the Supplements volume and that not only applies to cervical cancer
screening but also HPV vaccination [3,14].
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